drugset / Trial / NCT01391507

Pilot Study of COR-1 in Heart Failure

NCT01391507 ↗

Phase 2 Completed 36 enrolled Corimmun GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the effect of COR-1 in combination with standard therapy in patients with heart failure. The safety and tolerability of COR-1 will also be assessed.

Timeline

Start
2011-10
Primary completion
2013-08
Completion
2013-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject COR-1 Peptide 20 mg Intravenous
Subject COR-1 Peptide 80 mg Intravenous
Subject COR-1 Peptide 160 mg Intravenous